关于司美格鲁肽口服片，问得最多的10个问题

Core Viewpoint - The article addresses common questions regarding the oral formulation of Semaglutide for weight loss, emphasizing its effectiveness, usage guidelines, and safety profile while highlighting ongoing clinical trials and research findings [4]. Group 1: Weight Loss Efficacy - In the OASIS 1 study, participants using 50mg oral Semaglutide lost an average of 17.4% (18.34 kg) over 68 weeks [5][6]. - The OASIS 4 study showed that participants using 25mg oral Semaglutide lost an average of 13.6% (14.4 kg) over 64 weeks, with potential weight loss reaching 16.6% (17.6 kg) if all subjects completed the treatment [7][8]. Group 2: Side Effects and Safety - Approximately 30% of participants reported gastrointestinal side effects, which were mostly mild to moderate and tended to resolve over time [9]. - Semaglutide has shown good safety in elderly patients and those with renal impairment, although caution is advised for patients with severe renal dysfunction [11]. Group 3: Usage Guidelines - Semaglutide should be taken at least 30 minutes before the first meal of the day, using no more than 118ml of water, and should not be crushed or chewed [12]. - The recommended starting dose is 3mg once daily, increasing to 7mg after 30 days, with a maximum dose of 14mg if necessary [12]. Group 4: Lifestyle Changes - Weight loss should not solely rely on dieting; a balanced intake of at least 1200 calories per day is recommended, with a focus on healthy snacks [13]. - Adequate protein intake of at least 1g per kg of body weight is essential, and physical activity of 150-300 minutes per week is advised [15]. Group 5: Mechanism of Action - Semaglutide mimics GLP-1 hormone, improving insulin secretion and reducing appetite, while also slowing gastric emptying to prolong satiety [16]. - The SNAC technology enhances the absorption of Semaglutide, increasing its bioavailability by approximately 100 times [16]. Group 6: Contraindications - Semaglutide is not suitable for type 1 diabetes patients, those with severe gastrointestinal diseases, or individuals with a history of medullary thyroid carcinoma [18]. Group 7: Additional Benefits - Clinical trials have shown that Semaglutide effectively manages type 2 diabetes, with a 92.3% HbA1c target achievement rate among newly diagnosed patients in China [19]. - The PIONEER 6 study indicated a 51% reduction in cardiovascular death risk for patients using Semaglutide compared to placebo [21]. Group 8: Oral vs. Injectable Formulation - Oral Semaglutide is easier to store and transport compared to injectable forms, which require strict cold chain logistics [23]. - The oral formulation is more convenient for patients who may have a fear of injections [23]. Group 9: Risk of Hypoglycemia - Semaglutide's glucose-dependent mechanism means it does not cause hypoglycemia in individuals with normal blood sugar levels, making it safer for weight loss treatments [24]. Group 10: Weight Regain After Discontinuation - In studies, 18% of patients regained weight after stopping Semaglutide, while 56% maintained or continued to lose weight [25].